Comparison of three commercial one-dose porcine circovirus type 2 (PCV2) vaccines on PCV2 shedding in semen from experimentally infected boars

Fine mapping of linear B cell epitopes on capsid protein of porcine circovirus 3

Porcine circovirus type 3 (PCV3) is an emerging swine pathogen associated with acute porcine dermatitis and nephropathy syndrome (PDNS)-like clinical signs, reproductive failure, and multisystemic inflammation. Current evidence shows that PCV3 is spread worldwide, and its high incidence may pose a threat to the global pig industry. Capsid (Cap) protein is the sole structural protein which plays an important role in inducing protective immunity against PCV3 infection. In this study, monoclonal antibodies (mAbs) against Cap protein of PCV3 were produced by the hybridoma technique. Subsequently, 12 serial overlapping peptides (P1 to P12) spanning the entire region of Cap were synthesized to determine the B cell epitope regions using the mAbs. Results from dot-blot and peptide ELISA identified that P3, P9, and P10 were the major B cell antigenic regions. Fine mapping by shorter N- and C-terminal truncated peptides confirmed that the motifs ⁵⁷NKPWH⁶¹, ¹⁴⁰KHSRYFT¹⁴⁶, and ¹⁶¹QSLFFF¹⁶⁶ were linear B cell epitopes, which were highly conserved among different PCV3 strains. Interestingly, we found that the motif ¹⁴⁰KHSRYFT¹⁴⁶ was highly conserved in all reported types of PCVs (i.e., PCV1, PCV2, PCV3, and PCV4), except for the substitution (Y → K → R) of the first residue. This is the first research to identify B cell epitopes of PCV3 Cap, and these findings may lead to a better understanding of the antibody-antigen interaction and provide some guidance for PCV3 vaccine design.Key points• The recombinant Cap protein of PCV3 was expressed and purified in soluble form. • PCV3 Cap-specific mAbs prepared in this study had no cross-reactivity with PCV1/PCV2 Cap. • This is the first report of three conserved linear B cell epitopes on PCV3 Cap. • The minimal residues of the epitopes were 57-61 aa, 140-146 aa, and 161-166 aa.

The effect of porcine circovirus type 2 (PCV2) vaccination of male piglets on sperm quality at the age of puberty

The objective of the study was to investigate the effect of porcine circovirus type 2 (PCV2) vaccination in piglets on sperm quality of young boars. A total of 136 sows were divided in four groups of 34 animals each (17 vaccinated with Circovac®, Merial and 17 unvaccinated in each group). A total of 1 200 piglets were selected, half of which were vaccinated against PCV2 on the 21st day (Porcilis® PCV, MSD) and the other half was left unvaccinated. Four groups of 300 pigs each were formed as follows: PS group (vaccinated sows + piglets), S group (vaccinated sows + unvaccinated piglets), P group (unvaccinated sows + vaccinated piglets), C group (unvaccinated sows + piglets). Furthermore, 80 boars (20 piglets per group) were selected and slaughtered at the age of 5.5 months and weight of 95 ± 5.5 kg and their epididymal sperm was collected and evaluated for motility and kinetics, concentration and morphology. Additionally, 10 pigs from each group were used for blood sampling and serological testing for PCV2 IgM and IgG antibodies at the age of 21, 70, 110 and 150 days. The IgG and IgM patterns suggested that the piglets were coming into contact with PCV2 early in life. The S group demonstrated significantly lower curvilinear velocity (VCL, μm/s), amplitude of lateral head displacement (ALH, μm) and significantly higher head abnormalities (%) compared to other groups (P< 0.05). In conclusion, vaccinated young boars showed some improved epididymal sperm kinetic indices and head morphology.

Efficacy of a Commercial PCV2a Vaccine with a Two-Dose Regimen Against PCV2d

Porcine circovirus type 2, the causative agent of porcine circovirus associated diseases (PCVAD), consists of three major genotypes PCV2a, 2b and 2d. Current commercial vaccines contain the first-identified PCV2a’s capsid protein or whole virions. Outbreaks of PCVAD, caused by the recently identified PCV2d in vaccinated herds have raised concerns regarding the efficacy of current PCV2a vaccines against PCV2d. Thus, the primary objective of this study was to assess the efficacy of a two-dose regimen for the recently reformulated Fostera PCV MetaStim vaccine, to determine if reformulation with the squalene oil adjuvant and two-dose regimen improves the threshold of protection enough to eliminate viremia in a vaccination and challenge model. Two groups of seven pigs each were vaccinated with the commercial vaccine or PBS, and challenged with the PCV2d virus. Strong pre-challenge virus neutralizing responses were detected against all three genotypes. Post-challenge viremia was not completely eliminated as expected but a 2 log₁₀ mean reduction in viral load was achieved in vaccinated pigs. Vaccinated pigs had a mean score of 0 for pathological evaluation, while unvaccinated pigs had a score of 6.6. In conclusion, the reformulated Fostera PCV MetaStim PCV2a-based vaccine provided significant heterologous protection and was effective against PCV2d.

Comparative efficacy of experimental inactivated and live-attenuated chimeric porcine circovirus (PCV) 1-2b vaccines derived from PCV1 and PCV2b isolates originated in China

Background

Porcine circovirus type-2b (PCV2b) is recognized as the etiological agent of the various clinical manifestations of porcine circovirus-associated disease (PCVAD). Previous studies have demonstrated effectiveness of chimeric PCV1-2 vaccines against PCV2b challenge. In this study, the efficacy of inactivated and live-attenuated (2 × 10^3.5 or 2 × 10^4.0 50 % tissue culture infective dose [TCID₅₀] dose) chimeric PCV1-2b vaccines was compared side-by-side in conventional pigs.

Methods

Twenty-seven non-PCV2 viremic pigs without PCV2-specific antibody were randomly divided into six groups, including four vaccinated and challenged groups, a nonvaccinated challenged group, and a mock group. All pigs except those in the mock group were challenged at 28 days post vaccination (DPV) using PCV2b.

Results

Both inactivated and live-attenuated chimeric PCV1-2b vaccines induced a robust antibody responses, and significantly decreased microscopic lesion and lower viral loads in serum or superficial inguinal lymph nodes (SILN) compared with that in the nonvaccinated challenged group. PCV2 antibody titers decreased after 7 days post challenge (DPC) in pigs administered the inactivated PCV1-2b vaccine and they were lower than those in pigs inoculated with live-attenuated PCV1-2b on the day of necropsy. Moreover, no viremia was present in pigs inoculated with live-attenuated PCV1-2b vaccine at 21 DPC regardless of the dose difference.

Conclusions

The results demonstrated that both inactivated and live-attenuated chimeric PCV1-2b vaccines were effective to induce protective immunity against PCV2b infection.